Financial PerformanceSTXS delivered a strong 3Q performance and comfortably beat consensus expectations.
Product DevelopmentMAGiC approval in Europe is expected soon, with positive interactions in the U.S., potentially unlocking significant revenue opportunities.
Strategic GrowthStereotaxis is transforming its endovascular robotic offering with the addition of a new robot (GenesisX), new disposable (MAGiC), and platform optionality (new indications).